Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 06.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 25.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 13.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 26.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | er’s resignation from the Board as disclosed in Item 5.02 of this Current Report on Form 8-K. On September 26, 2024, t |
| 06.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer |
Stammdaten
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Unternehmen & Branche
| Name | ProPhase Labs, Inc. |
|---|---|
| Ticker | PRPH |
| CIK | 0000868278 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 540.019 USD |
| Beta | -0,32 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-09-30 | 10-Q | 883,000 | -6,839,000 | -0.16 | 65,702,000 | 6,861,000 |
| 2025-06-30 | 10-Q | 1,247,000 | -4,472,000 | -0.11 | 42,041,000 | 11,436,000 |
| 2025-03-31 | 10-Q | 1,431,000 | 3,966,000 | 0.11 | 50,111,000 | 15,118,000 |
| 2024-12-31 | 10-K | 6,770,000 | -53,364,000 | -2.61 | 63,200,000 | 7,353,000 |
| 2024-09-30 | 10-Q | 1,416,000 | -6,587,000 | -0.35 | 91,808,000 | 38,126,000 |
| 2024-06-30 | 10-Q | 1,504,000 | -6,153,000 | -0.33 | 93,678,000 | 44,076,000 |
| 2024-03-31 | 10-Q | 2,356,000 | -6,265,000 | -0.36 | 90,032,000 | 44,867,000 |
| 2023-12-31 | 10-K | 34,984,000 | -16,782,000 | -0.98 | 91,927,000 | 49,383,000 |
| 2023-09-30 | 10-Q | 8,365,000 | -5,141,000 | -0.30 | 91,710,000 | 56,428,000 |
| 2023-06-30 | 10-Q | 13,217,000 | -3,440,000 | -0.20 | 91,058,000 | 59,257,000 |
| 2023-03-31 | 10-Q | 19,303,000 | 550,000 | 0.03 | 95,374,000 | 59,941,000 |
| 2022-12-31 | 10-K | 122,647,000 | 18,463,000 | 1.02 | 87,648,000 | 63,631,000 |
| 2022-09-30 | 10-Q | 24,200,000 | 968,000 | 0.06 | 97,877,000 | 67,921,000 |
| 2022-06-30 | 10-Q | 29,100,000 | 7,446,000 | 0.40 | 97,947,000 | 68,157,000 |
| 2022-03-31 | 10-Q | 47,500,000 | 12,494,000 | 0.68 | 99,665,000 | 66,445,000 |
| 2021-12-31 | 10-K | 79,042,000 | 6,273,000 | 0.40 | 89,295,000 | 58,628,000 |
| 2021-09-30 | 10-Q | 9,500,000 | -3,978,000 | -0.26 | 72,630,000 | 48,264,000 |
| 2021-06-30 | 10-Q | 9,100,000 | -1,395,000 | -0.09 | 76,323,000 | 47,733,000 |
| 2021-03-31 | 10-Q | 15,300,000 | 1,057,000 | 0.06 | 85,444,000 | 52,665,000 |
| 2020-12-31 | 10-K | 14,514,000 | -2,125,000 | -0.18 | 31,405,000 | 10,556,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.